NEW DELHI, Oct 8 (Reuters) - Merck & Co's (MRK.N) experimental antiviral drug molnupiravir has not shown "significant efficacy" against moderate COVID-19, a source with the Drug Controller General of India said.

Aurobindo Pharma Ltd wants to discontinue a late-stage trial of molnupiravir in moderate COVID-19 patients, the regulator's expert committee said on Friday.

https://www.reuters.com/business/healthcare-p...021-10-08/